Citi Research reported that Sino Biopharm's (01177.HK) acquisition of Lixun Pharmaceutical will significantly expand its innovative product pipeline.
The note highlights Lixun's valuable assets, including: - LM-299 (PD-1/VEGF) licensed to Merck - LM-305 (GPRC5D ADC) licensed to AstraZeneca - LM-108 (CCR8 monoclonal antibody) - LM-302 (CLDN18.2 ADC)
This transaction represents a landmark in China's pharmaceutical sector as the industry's first major China-to-China acquisition. Citi maintains its "Buy" rating on Sino Biopharm with a HK$6.20 target price.
The research further notes significant progress in Sino Biopharm's innovative drug development: - TQC3721, the world's second-leading PDE3/4 inhibitor, initiated Phase III trials for COPD in June, demonstrating strong out-licensing potential - Pipeline assets including TQB6411 (EGFR/cMet ADC) and TQB3003 (fourth-generation EGFR TKI) have advanced to clinical stages
China's broader pharmaceutical and biotech industry continues to benefit from accelerating innovation and growing licensing trends.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.